Normal view MARC view ISBD view

Alpha interferon-2b as a modulator of ifosfamide plus cisplatin induction chemotherapy for advanced head and neck cancer

In Indian Journal of Medical and Pediatric Oncology
Contributor(s): Hiwase, Devendra K | Parikh DM | Mazumdar, Alaka T | RC Mistry | caninst@md2vsnl.net.in | Pai VR.
Material type: materialTypeLabelArticleSeries: Vol 23 Issues 1.Publisher: 2002Description: 13-16.Subject(s): Chemotherapy modulation | Alfa interferon-2b | Head and neck cancer | Neoplasms-drug therapyDDC classification: In: Indian Journal of Medical and Pediatric OncologySummary: We have reported a response rate of 65.7 per cent with ifosfamide and cisplatin combination in the treatment of advanced head and neck cancer.6 there have been promising new preliminary data to show that interferon with combination with chemotherapy can produce good response rate in patients with advanced head and neck cancer. Methods: All the patients with locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) are entered in this study. Eligible patients had to have histologically proven SCCHN, no prior chemotherapy, measurable disease, WHO performance status 0-2 normal renal, liver function, WBC greater than 4000, platelet count greater than 100,000 and Haemoglobin greater than 10gm. Treatment Plan: All patients were treated with ifosfamide 1.5 gm/m2 IV infusion D1 to D5, inj. mesna 400 mg iv push at 0, 4, 8 hours on D1 to D5, inj cisplatin 20 mg infusion on D1 to D5 and inj alpha interferon-2b 3 mu subcutaneously on D1 to D5. Tab paracetamol 500 mg PO was given thirty minute
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Articles Articles Tata Memorial Hospital
Available AR4581

We have reported a response rate of 65.7 per cent with ifosfamide and cisplatin combination in the treatment of advanced head and neck cancer.6 there have been promising new preliminary data to show that interferon with combination with chemotherapy can produce good response rate in patients with advanced head and neck cancer. Methods: All the patients with locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) are entered in this study. Eligible patients had to have histologically proven SCCHN, no prior chemotherapy, measurable disease, WHO performance status 0-2 normal renal, liver function, WBC greater than 4000, platelet count greater than 100,000 and Haemoglobin greater than 10gm. Treatment Plan: All patients were treated with ifosfamide 1.5 gm/m2 IV infusion D1 to D5, inj. mesna 400 mg iv push at 0, 4, 8 hours on D1 to D5, inj cisplatin 20 mg infusion on D1 to D5 and inj alpha interferon-2b 3 mu subcutaneously on D1 to D5. Tab paracetamol 500 mg PO was given thirty minute

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha